An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Latest Information Update: 03 Jun 2025
At a glance
- Drugs PTX 100 (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 03 Apr 2025 Status changed from not yet recruiting to recruiting.
- 11 Mar 2025 New trial record